Literature DB >> 11720318

Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998.

A L Wester1, M H Vatn, O Fausa.   

Abstract

BACKGROUND: Amyloidosis (A) is a well-known but rare complication to inflammatory bowel disease (IBD). We describe 18 patients with IBD and A, with special emphasis on clinicopathologic features and site relationships, comparing our results with previously reported cases in the world literature.
METHODS: Patient records were collected from the files of the medical department at Rikshospitalet. Clinical data were compiled from records.
RESULTS: Fifteen of the 18 patients had Crohn's disease (CD), 1 had ulcerative colitis (UC), one had UC preceding CD, and 1 had indeterminate colitis. There was a male preponderance of 13:5 = 2.6. Five of the patients had A at the time of diagnosis of IBD. Median time from diagnosis of IBD to A was 4 years, and A was diagnosed within 5 years after onset of IBD in 11 patients. Thirteen of the patients had suppurative complications; 12 had extraintestinal manifestations. Sixteen of the patients had been treated by bowel resection, 14 due to refractory IBD. Ten patients had been treated by renal transplantation. After 15 years of follow-up, the survival rate was 60%.
CONCLUSIONS: Our findings strengthen the previous impression of an approximately 3-fold increased preponderance in males, with at least 10-fold increased frequency in CD compared with UC, and with a possible relationship to suppurative complications and extraintestinal manifestations, as well as an increased risk of having a bowel resection. The increased survival seems to be due to the introduction of renal transplantation.

Entities:  

Mesh:

Year:  2001        PMID: 11720318     DOI: 10.1097/00054725-200111000-00003

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  15 in total

Review 1.  Treatment of the extraintestinal manifestations of inflammatory bowel disease.

Authors:  Charles N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  2002-12

2.  [Amyloid diagnostics in rheumatic diseases].

Authors:  C Röcken; J Ernst
Journal:  Pathologe       Date:  2006-11       Impact factor: 1.011

3.  Extraintestinal manifestations of inflammatory bowel disease.

Authors:  Jonathan S Levine; Robert Burakoff
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-04

Review 4.  Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.

Authors:  María Rojas-Feria; Manuel Castro; Emilio Suárez; Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

Review 5.  Renal manifestations in inflammatory bowel disease: a systematic review.

Authors:  Karen van Hoeve; Ilse Hoffman
Journal:  J Gastroenterol       Date:  2022-07-14       Impact factor: 6.772

6.  Inflammatory bowel disease and systemic AA amyloidosis.

Authors:  Prayman T Sattianayagam; Julian D Gillmore; Jennifer H Pinney; Simon D J Gibbs; Ashutosh D Wechalekar; Janet A Gilbertson; Dorota Rowczenio; Philip N Hawkins; Helen J Lachmann
Journal:  Dig Dis Sci       Date:  2013-01-31       Impact factor: 3.199

Review 7.  The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease.

Authors:  Tao Yang; Elaine M Richards; Carl J Pepine; Mohan K Raizada
Journal:  Nat Rev Nephrol       Date:  2018-07       Impact factor: 28.314

8.  The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease.

Authors:  Josephine M Ambruzs; Patrick D Walker; Christopher P Larsen
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-21       Impact factor: 8.237

Review 9.  Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease.

Authors:  Guru Trikudanathan; Preethi G K Venkatesh; Udayakumar Navaneethan
Journal:  Drugs       Date:  2012-12-24       Impact factor: 9.546

Review 10.  Systemic amyloidosis and the gastrointestinal tract.

Authors:  Prayman T Sattianayagam; Philip N Hawkins; Julian D Gillmore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-01       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.